Principle of targeted therapy and mechanism of action of Momelotinib on myelofibrosis

Momelotinib is an oral small molecule tyrosine kinase inhibitor that mainly targets JAK1 and JAK2 kinases and has therapeutic potential for primary or secondary myelofibrosis (MF). Its mechanism of action is based on inhibiting the excessive activation of the JAK-STAT signaling pathway, which is the core link in the pathogenesis of myelofibrosis. By blocking abnormal JAK1/JAK2 activity, molotinib can reduce the production of pro-inflammatory cytokines, thereby inhibiting the progression of myelofibrosis and improving the bone marrow hematopoietic microenvironment.

In patients with myelofibrosis, overactivation of the JAK-STAT signaling pathway can lead to abnormal hematopoietic stem cell proliferation, increased secretion of fibrosis factors, and aggravation of bone marrow stromal fibrosis. By specifically inhibiting JAK1/JAK2, molotinib regulates abnormal signals, reduces the degree of myelofibrosis, and reduces the levels of inflammatory factors. This effect not only helps improve bone marrow function, but also reduces symptoms related to hemodynamic abnormalities such as hepatosplenomegaly.

In addition, molotinib also has the potential to improve anemia symptoms in patients with myelofibrosis. Studies have shown that the drug helps improve erythropoiesis by inhibiting abnormal activation of JAK2 while regulating iron homeostasis and erythropoietin signaling, thereby alleviating anemia. Compared with traditional JAK inhibitors, molotinib shows certain advantages in improving anemia and provides patients with a more comprehensive treatment option.

In general, molotinib inhibits abnormal signaling by targetingJAK1/JAK2, which can not only slow down the progression of myelofibrosis, but also improve anemia and inflammatory symptoms and optimize the bone marrow hematopoietic environment. Its unique dual mechanism of action gives it high clinical application potential in the treatment of myelofibrosis, providing a new targeted therapy option for patients with refractory MF.

Reference materials:https://www.drugs.com/